Home > Browse Issues > Vol.40 No.2

The Effect of Overexpression of TPX2 Gene on Proliferation and Cell Cycle in Human Cervical Cancer Hela Cells and Its Mechanism


Chang Haiping*, Yang Cairong, Song Shufang, Ren Jie, Zheng Jian, Zhang Long
The Department of Obstetrics and Gynecology, the Affiliated Hospital of Inner Mongolia Medical College, Hohhot 010050, China
Abstract: This article aimed to investigate the effects of TPX2 overexpression on proliferation and cell cycle of cervical cancer Hela cells, and explore its possible mechanism. Lentiviral vectors carrying TPX2 was successfully constructed. Hela cells were stablily infected Lentiviral vectors (LV11-TPX2) as the experimental group. Hela cells were stablily infected Lentiviral vectors (LV11-NC) as negative control group. Hela cells noninfected Lentiviral vectors as the blank control group (CON). The proliferation and cell cycle distribution were determined by CCK-8 and colony formation assay and FCM, respectively. The levels of Aurora A, eg5, P53, Ki67, CyclinB2 and PCNA proteins were detected by Western blot. The result showed that compared with blank control group and negative control group, the proliferative ability of Hela cells in LV11-TPX2 group detected by CCK-8 was significantly increased (both, P<0.05), and the number of clones in LV11-TPX2 group is more than that in negative control group and blank control group detected by colony formation assay (both, P<0.05). The percentages of G2 and S phase cells are significantly increased in LV11-TPX2 group detected by FCM (both, P<0.05). The level of P53 was down-regulated. The levels of Aurora A, eg5, Ki67, CyclinB2 and PCNA were up-regulated in LV11- TPX2 group detected by Western blot (all, P<0.05). In conclusion, overexpression TPX2 gene can promote the proliferation of cervical cancer cells, increase the percentage of G2 and S phase cells in the cell cycle, which may be related to down-regulation of P53 protein level and up-regulation Aurora A, eg5, Ki67, CyclinB2, PCNA protein levels in Hela cells.


CSTR: 32200.14.cjcb.2018.02.0002